Spago Nanomedical Past Earnings Performance
Past criteria checks 0/6
Spago Nanomedical's earnings have been declining at an average annual rate of -21.5%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been declining at an average rate of 34.1% per year.
Key information
-21.5%
Earnings growth rate
13.0%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | -34.1% |
| Return on equity | -100.4% |
| Net Margin | -572.4% |
| Next Earnings Update | 21 Aug 2024 |
Recent past performance updates
Recent updates
Most Shareholders Will Probably Agree With Spago Nanomedical AB (publ)'s (STO:SPAGO) CEO Compensation
Jun 04
We're Not Worried About Spago Nanomedical's (STO:SPAGO) Cash Burn
Sep 21We're Interested To See How Spago Nanomedical (STO:SPAGO) Uses Its Cash Hoard To Grow
May 26Loss-Making Spago Nanomedical AB (publ) (STO:SPAG) Set To Breakeven
Mar 30We're Hopeful That Spago Nanomedical (NGM:SPAG) Will Use Its Cash Wisely
Feb 03
Loss-Making Spago Nanomedical AB (publ) (NGM:SPAG) Expected To Breakeven In The Medium-Term
Dec 11Revenue & Expenses Breakdown
How Spago Nanomedical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 6 | -34 | 24 | 0 |
| 31 Dec 23 | 6 | -42 | 24 | 0 |
| 30 Sep 23 | 7 | -42 | 24 | 0 |
| 30 Jun 23 | 8 | -43 | 25 | 0 |
| 31 Mar 23 | 6 | -45 | 25 | 0 |
| 31 Dec 22 | 6 | -39 | 25 | 0 |
| 30 Sep 22 | 6 | -39 | 25 | 0 |
| 30 Jun 22 | 6 | -41 | 24 | 0 |
| 31 Mar 22 | 6 | -43 | 24 | 0 |
| 31 Dec 21 | 6 | -39 | 24 | 0 |
| 30 Sep 21 | 7 | -32 | 23 | 0 |
| 30 Jun 21 | 7 | -27 | 22 | 0 |
| 31 Mar 21 | 7 | -20 | 20 | 0 |
| 31 Dec 20 | 7 | -19 | 19 | 0 |
| 30 Sep 20 | 7 | -20 | 21 | 0 |
| 30 Jun 20 | 13 | -21 | 22 | 0 |
| 31 Mar 20 | 16 | -21 | 23 | 0 |
| 31 Dec 19 | 19 | -20 | 23 | 0 |
| 30 Sep 19 | 25 | -18 | 22 | 0 |
| 30 Jun 19 | 25 | -15 | 21 | 0 |
| 31 Mar 19 | 27 | -13 | 21 | 0 |
| 31 Dec 18 | 30 | -11 | 20 | 0 |
| 30 Sep 18 | 30 | -11 | 20 | 0 |
| 30 Jun 18 | 27 | -10 | 19 | 0 |
| 31 Mar 18 | 23 | -10 | 19 | 0 |
| 31 Dec 17 | 18 | -9 | 18 | 0 |
| 30 Sep 17 | 13 | -8 | 16 | 0 |
| 30 Jun 17 | 12 | -8 | 15 | 0 |
| 31 Mar 17 | 11 | -7 | 15 | 0 |
| 31 Dec 16 | 11 | -8 | 15 | 0 |
| 30 Sep 16 | 9 | -7 | 14 | 0 |
| 30 Jun 16 | 8 | -7 | 13 | 0 |
| 31 Mar 16 | 8 | -7 | 13 | 0 |
| 31 Dec 15 | 8 | -7 | 12 | 0 |
| 30 Sep 15 | 7 | -8 | 13 | 0 |
| 30 Jun 15 | 7 | -7 | 12 | 0 |
| 31 Mar 15 | 7 | -7 | 12 | 0 |
| 31 Dec 14 | 8 | -6 | 11 | 0 |
| 30 Sep 14 | 7 | -7 | 11 | 0 |
| 30 Jun 14 | 9 | -7 | 11 | 0 |
| 31 Mar 14 | 8 | -5 | 10 | 0 |
| 31 Dec 13 | 8 | -5 | 10 | 0 |
| 30 Sep 13 | 10 | -4 | 10 | 0 |
| 30 Jun 13 | 9 | -4 | 10 | 0 |
Quality Earnings: SPAGO is currently unprofitable.
Growing Profit Margin: SPAGO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SPAGO is unprofitable, and losses have increased over the past 5 years at a rate of 21.5% per year.
Accelerating Growth: Unable to compare SPAGO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPAGO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: SPAGO has a negative Return on Equity (-100.41%), as it is currently unprofitable.